Fig. 5.
Fig. 5. Expression profile of Lyp1 and Lyp2 transcripts. (A) Two micrograms of poly A+ RNA from various human tissues and cell lines (OCI/AML3, acute myeloblastic leukemia cell line; K562, erythroleukemia cell line; and U937, monocytes cell line) were hybridized with a 1.3-kb cDNA probe common to both Lyp1 and Lyp2 (exposure time, 7 days) and with actin (exposure time, 24 hours). (B) RNA from immune relevant human tissues (Clontech) was blotted first with a cDNA probe from the unique 280-bp 3′ nucleotides sequence of Lyp2 (including the untranslated sequence) and then, after stripping, with a 600-bp cDNA probe from the unique 3′ nucleotide sequence of Lyp1 (exposure time, 7 days) and with actin (exposure time, 24 hours). The sizes of the RNA markers are indicated in kilobases.

Expression profile of Lyp1 and Lyp2 transcripts. (A) Two micrograms of poly A+ RNA from various human tissues and cell lines (OCI/AML3, acute myeloblastic leukemia cell line; K562, erythroleukemia cell line; and U937, monocytes cell line) were hybridized with a 1.3-kb cDNA probe common to both Lyp1 and Lyp2 (exposure time, 7 days) and with actin (exposure time, 24 hours). (B) RNA from immune relevant human tissues (Clontech) was blotted first with a cDNA probe from the unique 280-bp 3′ nucleotides sequence of Lyp2 (including the untranslated sequence) and then, after stripping, with a 600-bp cDNA probe from the unique 3′ nucleotide sequence of Lyp1 (exposure time, 7 days) and with actin (exposure time, 24 hours). The sizes of the RNA markers are indicated in kilobases.

Close Modal

or Create an Account

Close Modal
Close Modal